New Therapies for Treatment-Resistant Schizophrenia
Treatment-resistant schizophrenia (TRS) poses significant challenges, affecting up to 33% of schizophrenia patients who experience minimal relief from standard antipsychotics. While clozapine represents a cornerstone of TRS management, its limitations necessitate alternatives. Exploring new therapies like cariprazine, and augmentation methods, including psychotherapy and understanding neurobiological intricacies, can guide improved and personalized patient care. Understanding Schizophrenia […]
3 minute read